Z Ping Lin
Overview
Explore the profile of Z Ping Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ratner E, Zhu Y, Penketh P, Berenblum J, Whicker M, Huang P, et al.
Br J Cancer
. 2016 Mar;
114(7):777-86.
PMID: 26964031
Background: Platinum resistance may be attributable to inherent or acquired proficiency in homologous recombination repair (HRR) in epithelial ovarian cancer (EOC). The objective of this study was to evaluate the...
12.
Ishiguro K, Lin Z, Penketh P, Shyam K, Zhu R, Baumann R, et al.
Biochem Pharmacol
. 2014 Aug;
91(3):312-22.
PMID: 25130544
Triapine, currently being evaluated as an antitumor agent in phase II clinical trials, and its terminally dimethylated derivative Dp44mT share the α-pyridyl thiosemicarbazone backbone that functions as ligands for transition...
13.
Lin Z, Ratner E, Whicker M, Lee Y, Sartorelli A
Mol Cancer Res
. 2014 Jan;
12(3):381-393.
PMID: 24413181
Unlabelled: PARP inhibitors exploit synthetic lethality to target epithelial ovarian cancer (EOC) with hereditary BRCA mutations and defects in homologous recombination repair (HRR). However, such an approach is limited to...
14.
Ratner E, Sartorelli A, Lin Z
Curr Opin Oncol
. 2012 Jul;
24(5):564-71.
PMID: 22759740
Purpose Of Review: Management of the epithelial ovarian cancer (EOC) remains a therapeutic challenge, with continued poor overall survival (OS). Given low chemotherapy response rates for recurrent disease and short...
15.
Lin Z, Lee Y, Lin F, Belcourt M, Li P, Cory J, et al.
Mol Pharmacol
. 2011 Aug;
80(6):1000-12.
PMID: 21875941
Ribonucleotide reductase (RNR) catalyzes the rate-limiting step in the production of deoxyribonucleoside triphosphates (dNTPs) required for replicative and repair DNA synthesis. Mammalian RNR is a heteromeric enzyme consisting primarily of...
16.
Lin Z, Zhu Y, Johnson D, Rice K, Nottoli T, Hains B, et al.
Mol Pharmacol
. 2007 Oct;
73(1):243-51.
PMID: 17959714
Multidrug resistance protein 4 (MRP4; ABCC4) is a member of the MRP/ATP-binding cassette family serving as a transmembrane transporter involved in energy-dependent efflux of anticancer/antiviral nucleotide agents and of physiological...
17.
Eaton J, Lin Z, Sartorelli A, Bonawitz N, Shadel G
J Clin Invest
. 2007 Sep;
117(9):2723-34.
PMID: 17786248
Ataxia-telangiectasia mutated (ATM) kinase orchestrates nuclear DNA damage responses but is proposed to be involved in other important and clinically relevant functions. Here, we provide evidence for what we believe...
18.
Lin Z, Belcourt M, Carbone R, Eaton J, Penketh P, Shadel G, et al.
Biochem Pharmacol
. 2006 Dec;
73(6):760-72.
PMID: 17188250
Ribonucleotide reductase (RNR), which consists of R1 and R2 subunits, catalyzes a key step of deoxyribonucleoside triphosphate (dNTP) synthesis for DNA replication and repair. The R2 subunit is controlled in...
19.
Muramatsu T, Johnson D, Finch R, Johnson L, Leffert J, Lin Z, et al.
Oncol Res
. 2004 Aug;
14(7-8):331-43.
PMID: 15301424
The impact of mouse multidrug resistance genes mdrla/b and mrpl on age-related differences in the toxicity and biodistribution of vincristine (VCR) was evaluated in wild-type, mrpl(-/-), mdrla/b(-/-), and combined mdrla/b(-/-),...
20.
Zeng H, Lin Z, Sartorelli A
Biochem Pharmacol
. 2004 Aug;
68(5):911-21.
PMID: 15294454
Overexpression of human MDR1 P-glycoprotein [Pgp] is associated with cellular resistance to bulky amphipathic drugs, such as taxol, anthracyclines, vinca alkaloids, and epipodophyllotoxins by actively effluxing drugs from cells. We...